IN Therapeutics(INT) is a spin-out subsidiary of Daewoong Pharma, one of the local leading pharma company in Korea.
INT is a research-oriented company fully entitled to develop the first-in class drugs of ion channels for neurological disorder.
1.Ion channel platform (VITVO):
One-stop assessment platform specific to ion channel, utilizing auto patch clamping technique from library Screening to Efficacy/PoC confirmation at Live animal model
2.Pipeline: We have platform based pipelines for neurological disorder- pain, hearing loss, and ALS.
Leading pipeline targeting for OA pain currently at clinical stage- with its key advantages of state-dependent inhibition, enhanced target engagement (low PPB) and selectivity, iNT demonstrated superior efficacy over non-steroidal and weak opioid
iNT successfully closed Series A rounding raising 40mil USD. The funding involved local named investors.
iNT will involve international investors for Series B considering international IPO
INT is a research-oriented company fully entitled to develop the first-in class drugs of ion channels for neurological disorder.
1.Ion channel platform (VITVO):
One-stop assessment platform specific to ion channel, utilizing auto patch clamping technique from library Screening to Efficacy/PoC confirmation at Live animal model
2.Pipeline: We have platform based pipelines for neurological disorder- pain, hearing loss, and ALS.
Leading pipeline targeting for OA pain currently at clinical stage- with its key advantages of state-dependent inhibition, enhanced target engagement (low PPB) and selectivity, iNT demonstrated superior efficacy over non-steroidal and weak opioid
iNT successfully closed Series A rounding raising 40mil USD. The funding involved local named investors.
iNT will involve international investors for Series B considering international IPO
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2020
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
iN1011-N17 (Nav1.7 inhibitor) currently at clinical stage in Australia
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
less than 10
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
